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Abstract
Background: Increasing the predictability and reducing the rate of side effects of
oral anticoagulant treatment (OAT) requires further clarification of the cause of about
50% of the interindividual variability of OAT response that is currently unaccounted
for. We explore numerically the hypothesis that the effect of the interindividual
expression variability of coagulation proteins, which does not usually result in a
variability of the coagulation times in untreated subjects, is unmasked by OAT.
Results: We developed a stochastic variant of the Hockin-Mann model of the tissue
factor coagulation pathway, using literature data for the variability of coagulation
protein levels in the blood of normal subjects. We simulated in vitro coagulation and
estimated the Prothrombin Time and the INR across a model population. In a model
of untreated subjects a “canalization effect” can be observed in that a coefficient of
variation of up to 33% of each protein level results in a simulated INR of 1 with a
clinically irrelevant dispersion of 0.12. When the mean and the standard deviation of
vitamin-K dependent protein levels were reduced by 80%, corresponding to the
usual Warfarin treatment intensity, the simulated INR was 2.98 ± 0.48, a clinically
relevant dispersion, corresponding to a reduction of the canalization effect.
Then we combined the Hockin-Mann stochastic model with our previously published
model of population response to Warfarin, that takes into account the genetical and
the phenotypical variability of Warfarin pharmacokinetics and pharmacodynamics. We
used the combined model to evaluate the coagulation protein variability effect on
the variability of the Warfarin dose required to reach an INR target of 2.5. The dose
variance when removing the coagulation protein variability was 30% lower. The dose
was mostly related to the pretreatment levels of factors VII, X, and the tissue factor
pathway inhibitor (TFPI).
Conclusions: It may be worth exploring in experimental studies whether the
pretreatment levels of coagulation proteins, in particular VII, X and TFPI, are
predictors of the individual warfarin dose, even though, maybe due to a canalization-
type effect, their effect on the INR variance in untreated subjects appears low.
Keywords: Interindividual variability, stochastic model, oral anticoagulant treatment,
INR, coagulation cascade, canalization
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There is a continuing need to identify measurable causes of the substantial variability
of the individual response to oral anticoagulants, such as warfarin or acenocoumarol.
Finding such causes is required to improve predictability and consequently reduce the
high levels of morbidity and mortality associated to these treatments. Together with
anthropometric parameters, the known polymorphisms of CYP2C9 and VKORC1
enzymes currently account only for about 50% of the dose variability [1-3].
The relation between measurable sources of variability and the variability of the
patient response to treatment is explained by the complex but extensively explored
warfarin pharmacokinetics/pharmacodynamics (PK/PD).
In short, Warfarin is absorbed from the gut completely, then it blocks irreversibly the
Vitamin-K epoxyde reductase complex 1 (VKORC1), an enzyme found mostly in the
liver. It is eliminated by other liver enzymes, from the cytochrome P-450 family, mostly
by CYP450-2C9. The blocking of the VKORC1 results in a depletion of reduced Vita-
min-K that is oxidised by the g-glutamyl-carboxylase enzyme (GGCX) symultaneously
with the g-carboxylation of the glutamate residues of protein precursors of coagulation
factors II,VII,IX and X. The g-carboxylation is necessary for their biological activity.
The variability of this PK/PD process can be due to: genetic mutations of CYP2C9,
VKORC1 and GGCX; mutations in the introns, exons or flanking sequences of these
enzymes resulting in different phenotypical expression; variability in intake, transport
and metabolism of vitamin-K; the size of the various organism compartments and in
particular of the liver; the general synthesis capacity of the liver; simultaneous adminis-
tration of drugs and foods that interact with various stages of the process, for example
by inducing or repressing the expression of CYP450 enzymes.
The synthesis rate of coagulation factors, and their biological activity is also variable
due to a number of mutations affecting both th es t r u c t u r ea n dt h ee x p r e s s i o nr a t eo f
the precursors. The elimination rate is probably influenced by the general activation
rate of the coagulation cascade in the bloodstream that also presents interindividual
variability.
One potential cause of the response variability that has not been generally considered
is that due to the genetic polymorphism and phenotypical expression of the proteins
that intervene in the coagulation cascade. Their effect on the coagulation time, for
example on the prothrombin time and its standardised equivalent–the International
Normalised Ratio (INR), is low in the healthy population. Here we argue, based on a
stochastic version of a well studied model of the extrinsic pathway of the coagulation
cascade [4], that this effect should be low only in untreated subjects.
The canalization effect, [5,6] is the relative robustness of key physiologic parameters,
features and processes despite wide genetic and phenotypical variability of other fac-
tors, such as expression levels of proteins.
We believe this could be the case with the coagulation cascade: while there is sub-
stantial interindividual variability in the biological level of coagulation proteins, the cas-
cade is organised such that the key blood coagulation time parameter is maintained
within very narrow limits across the healthy population.
T h i sw o u l da l s oe x p l a i nw h yav e r ys u b s t a n tial reduction of the level of vitamin-K
dependent factors (II,VII,IX,X) needs to be obtained in order to observe a clinically
relevant prolongation of the prothrombin time.
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phenomenon is also supressed and the interindividual variability of the expression of
coagulation proteins in treated subjects becomes manifest and needs to be corrected
by adjusting the Warfarin dose.
Methods
The Hocking Mann model [4] is a system of ordinary differential equations that
describe the kinetics of the sythesis of active thrombin once tissue factor is added to a
sample of blood. It corresponds to the process that takes place in a test tube when the
prothrombin time is measured.
We developed a stochastic version of the Hockin-Mann model of the tissue factor
(extrinsic) pathway kinetics by replacing, in the equations from [4] the coefficients cor-
responding to the initial levels of factors II, V, VII, VIIa, VIII, IX, X, XI, antithrombin-
III and tissue factor pathway inhibitor (TFPI) with normally distributed, independent,
random variables. The coefficient of variation for each variable was estimated based on
direct experimental determinations available in the literature (see Table 1).
We used a 5nM concentration for the initial level of the tissue factor, consistent with
the conditions used when measuring the prothrombin time. We computed a simulated
prothrombin time as the reaction time needed for activated factor II to reach a con-
centration of 20 nM.
From the results we computed the equivalent of the prothrombin time for each rea-
lisation and the mean normal prothrombin time (MNPT), as in [7], by averaging the
normal prothrombin times. The INR (International Normalised Ratio) of a blood sample
is the ratio of the prothrombin time for that sample to the MNPT.
As previously described in reference [8] this approach, using the Hockin-Mann
model, leads to simulated results that are consistent with the experimentally observed
Table 1 Literature data on the dispersion of the coagulation protein levels
protein mean sd unit c.v.
(%)
reference
II (prothrombin) 99.6 11.9 % 11.95 Yamagishi 2010 [20]
V (proaccelerin) 105.4 33.6 % 31.88 Yamagishi 2010 [20]
VII (proconvertin) 112.0 30.0 % 26.78 Folsom 1997 [21]
130.0 33.0 % 25.38 Cushman 1996 [13]
98.0 20.7 % 21.12 Feng 2000 [12]
1, non-cvd
99.5 26.2 % 26.33 Feng 2000 [12]
1, non-thrombotic cvd
93.6 31.7 % 33.87 Feng 2000 [12]
1, thrombotic cvd
VIII 120.0 37.0 % 30.83 Cushman 1996 [13]
127.0 40.0 % 31.50 Folsom 1997 [21]
IX 88.5 29.3 % 33.11 Yamagishi 2010 [20]
X (prothrombinase) 102.9 25.8 % 25.07 Yamagishi 2010 [20]
XI 84.1 19.7 % 23.42 Yamagishi 2010 [20]
Antithrombin-III 109.0 20.0 % 18.35 Folsom 1997 [21]
TFPI 36.4 12.8 ng/ml 35.16 Zakai 2010 [22]
Literature experimental data on the dispersion of coagulation protein biological levels in the general population, as used
in our simulations. In each case we computed C.V., the coefficient of variation, that is the ratio of the reported sd
(standard deviation) to the reported mean. The unit used in most reports is a percentage from a standard laboratory
value that is taken as 100% and is assumed close to the population average.
Values marked with ‘
1’ were estimated from the standard error of the mean and the number of cases from each groups
of cvd (cardiovascular disease) patients.
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reported in reference [9].
We simulated this model with a Monte Carlo implementation, by sampling the space of
the variables and computing the kinetics of each of the species as proposed by Gillespie
[10]. Each realisation corresponds to a simulated individual, and the whole dataset repre-
sents a simulation of the sample of the normal population.
The presence of stable anticoagulant treatment was simulated by uniformly reducing
the initial levels of factors II, VII (and VIIa), IX and X down to 20%. The proportional
reduction was applied to each case in the randomly generated set, thus resulting in the
reduction of both the mean and the standard deviation of the initial values of each
variable.
We then combined the stochastic Hockin-Mann model with our 2008 stochastic
model of warfarin pharmacodynamics [11], which is a detailed simulation of the
kinetics of warfarin absorption, elimination, binding to VKORC1; vitamin K cycle; coa-
gulation factor synthesis, g-carboxylation, release and elimination. It is a set of ordinary
differential equations with stochastic coefficients that represent interindividual
variabilities.
This model was tuned with data in a population of mostly Caucasian adults and is
able to reproduce the dynamics of INR response and dose variability as found in the
literature.
In the combined system we computed the INR using a Hocking-Mann simulation
instead of the formula from [9]. Thus, for each individual case, new initial parameters
were added, consisting of the initial levels of the species involved in the HM model. The
levels of coagulation proteins were generated as independent Gaussian variables with a
coefficient of variation as specified in table 1 (the median value was taken when multiple
literature determinations were available). Two series of Monte Carlo simulations were
run: (A) in which an average value of the baseline coagulation factor levels was taken to be
the same for all cases in the random set of parameters, but other individual parameters
(VKORC1, CYP2C9, antropometric differences) were kept variable; (B) in which the vari-
abilities present in table 1 were also included in the baseline parameter generation.
Results and Discussion
Baseline factor levels vs INR
As previously detailed in the methods section, we first simulated the coagulation of
normal blood samples using a stochastic version of the Hockin-Mann extrinsic coagu-
lation pathway model.
Figure 1 shows the distribution of the simulated INR values at various levels of the
vitamin K dependent factors (II, VII, IX and X), following different treatment intensi-
ties. The baseline level (100%) simulated sample resulted in a standard deviation of the
INR of 0.12.
For the highest treatment intensity, corresponding to an average INR of about 3,
despite reducing the levels–and implicitly the dispersion–of the vitamin K dependent
factors to 20% the standard deviation of the INR increased to 0.48.
This result suggests that measuring the baseline levels of coagulation factors before
treatment initiation might help with predicting the patient’s sensitivity. As such
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the strongest association with the INR.
Figures 2 and 3 show the relationship between the simulated level of each coagula-
tion protein and the level of the INR in the healthy and treated scenarios, respectively.
Proconvertin and proaccelerin (factor VII and V) were important determinants of the
INR value in untreated models. In the treated models factor V levels were not corre-
lated with the INR value anymore, but factors VII, X and the TFPI were.
Baseline factor levels and the warfarin dose
We combined our previously developed model of the population response to warfarin
[11] with the Hockin-Mann model for computing the instantaneous INR values.
We ran two series of Monte Carlo simulations: one (series A) in which the normal
variability of both the pharmacokinetic/pharmacodynamic (PK/PD) and the factor
variability were represented and a second (series B) in which the PK/PD variability was
represented but all baseline levels of the coagulation proteins were the same in all
cases.
20% 30% 40% 50% 60% 70% 80% 90% 100%
0
1
2
3
4
5
6
7
fraction of vit K dependent factors
I
N
R
Figure 1 Variability of the simulated INR by treatment intensity. Each boxplot represents the
distribution of INR values (reaction times relative to normal average) in a set of simulations. The biological
levels of all coagulation proteins have been specified with truncated Gaussian distributions, taking the
Hockin-Mann default values as means and applying the coefficient of variation from the literature reports in
humans (table 1) to compute the standard deviation. The vitamin-K dependent factors were then reduced to
the level specified on the x axis, corresponding to progressive treatment intensities. Horizontal lines in boxes
represent the first, second and third quartiles. Dots represent outliers. The figure shows that the variability of
the INR values increases when the levels of the vitamin-K dependent factors are decreasing.
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Page 5 of 10For each case in each Monte Carlo series we searched for the optimal daily dose of
Warfarin for a target INR.
For a therapeutic INR target of 2.5, the dose in the population was 4.03 ± 1.67 mg/
day in series B and 3.88 ± 2.00 mg/day in series A. Variances were 2.79 and 4.00; thus
elimination of baseline variability of coagulation proteins led to a reduction of the
simulated dose variance by 30%.
Table 2 shows the correlation coefficients between the baseline levels of the coagula-
tion proteins proteins and the dose. Correlations with the dose were also stronger for
factors VII, X and the TFPI.
Discussion
Biological activity levels of plasma proteins involved in coagulation have been docu-
mented to exhibit a wide variability in normal subjects (see references from table 1).
The fact this variability does not translate into an easily measurable variability of coa-
gulation test results, such as the INR, that are based on measuring coagulation times
in standardised conditions, is known in biology as “canalization” [5].
As a physiologic parameter, the optimal blood coagulation time is determined by the
balance of the need to keep the blood flowing through all the blood vessels as long as
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Figure 2 Individual factor levels vs the INR in scenarios representing untreated subjects.V i t a m i n - K
dependent factors are at the baseline (pretreatment) level. R is the Pearson correlation coefficient for each
plot. Each cross represents one point in the parameter space. The plot shows that factors V and VII have
the strongest correlations with the baseline INR.
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Page 6 of 10the organism is intact and the need for it to clot following any wounding. Over the
time of the evolution, the elimination of organisms that do not meet these two simul-
taneous and opposite constraints may have amounted to a “stabilizing selection”
process that resulted in the canalization effect.
Despite its low effect on the INR, the normal variability of the baseline levels of some
of these proteins (II, VII, TFPI, VIII, von Willebrand factor) has been associated with
the risk of cardiovascular events such as myocardial infarction and stroke [12,13]. This
illustrates how a “canalized” effect, such as the normally low variability of the
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Figure 3 Individual factor levels vs the INR in scenarios representing treated subjects.V i t a m i n - K
dependent factors are at 20% of the baseline level. Same conventions as in figure 2. Factors VII, X, and
TFPI appear to have the strongest correlation with the INR.
Table 2 Correlation coefficients (R) of optimal warfarin dose vs. baseline coagulation
protein levels
protein R
Factor II 0.09
Factor V 0.07
Factor VII 0.32
Factor X 0.24
Factor VIII 0.09
TFPI -0.30
AT-III -0.01
The strongest correlations were found for factors VII, X and the tissue factor pathway inhibitor (TFPI).
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pathological variability.
Our results suggest a similar effect may occur with the response to anticoagulant
treatment: while pretreatment coagulation times exhibit a low variability, the underly-
ing variability of the coagulation protein levels may be related to clinically relevant
differences in treatment response.
In this simulation study we explored the relationship between the variability of the
pretreatment plasmatic factor levels and the variability of the coagulation time. We
showed that the canalization effect should also be reduced when oral anticoagulation
of the same intensity is applied to all the simulated patients, unmasking the effect of
interindividual pretreatment factor variability on the INR only for patients under
treatment. We also show that, when warfarin doses are adjusted such that the same
INR target is achieved, the interindividual variability of pretreatment coagulation
protein levels in the blood should result in an interindividual variability of the neces-
sary dose.
These factors are influenced by a variety of known genetic polymorphisms [14-16]
but the influence of each polymorphism is relatively small and also there are other,
important, phenotypical and transient influences [17,18]. Thus, determination of their
baseline biological levels rather than their genotype should be most effective as INR
response predictors. Assays used for accurately measuring coagulation protein levels in
the blood are currently quite expensive; however, if the possible association described
here is confirmed experimentally more practical pretreatment investigations, such as
coagulation tests complementary to INR determination, might be developed.
Limitations
A limitation of our study is that we only considered a kinetic model of the extrinsic
pathway of the coagulation cascade. Although this model was extensively validated
with in vitro experimental data over the years, the particular implications we antici-
pated in this study need direct experimental verification as well.
The predictive value of the baseline coagulation protein levels may be lower than we
expect as in our model we considered their synthesis and elimination processes stable
in time for a given individual. The intraindividual variability [17,18] as well as inac-
curacies of factor level measurement methods [19] may result in an actually lower pre-
dictive value.
Conclusion
Our simulations suggest that in theory, to the extent of the validity of the Hockin-Mann
model and our warfarin population effect model, the pretreatment levels of the coagula-
tion proteins, in particular of factors X, VII and the TFPI may contribute to the variabil-
ity of the response to warfarin. If experimental verification confirms our numeric
predictions, measurement of the baseline levels of these proteins may further improve
warfarin dose prediction.
We suspect that this type of effect –an unmasking of interindividual variability when
some canalization effect is overcome–might also affect other types of treatments and
pathological conditions and explain other causes of unexpected variability of the individual
response.
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